secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021425
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M
--------------------------------------------------------------------------------

- At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.
- CRS for JANX007 only Grade 1/2 and transient; doses up to 3 mg with no MTD reached.
- JANX008: One NSCLC subject with confirmed PR (100% lung target reduction, liver mets eliminated); no CRS or TRAEs.
- 11 heavily pre-treated subjects enrolled across four tumor types in JANX008; no SAEs or DLTs.
- Preliminary cash, equivalents, and short-term investments ~$338.2M as of Jan 31, 2024 (incl. $0.8M restricted).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024021425/0000950170-24-021425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024021425/janx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer